Oragenics, Inc. announced it received an unqualified audit opinion for its 2025 financial statements, but with an explanatory paragraph highlighting concerns about its ability to continue as a going concern. This means the auditors found the financials fairly presented but noted risks about the company's future viability. The company is developing brain-targeted therapeutics using intranasal delivery technology, with its lead drug candidate in Phase IIa trials for concussion and mild traumatic brain injury. Investors should monitor upcoming clinical and financial developments closely.
Cycurion received a Nasdaq delisting notice due to its stock price falling below the $1 minimum for 31 consecutive days. The company is appealing the decision, which allows its shares to keep trading on Nasdaq during the review. Cycurion is focused o...
TDb Split Corp. plans a 15-for-100 share split for its Class A shares, effective for shareholders of record on July 24, 2026, pending TSX approval. Following the split, shareholders will receive the same $0.05 monthly cash distribution per share, eff...
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
